Analystreport

Aimmune Therapeutics Inc (NASDAQ: AIMT) had its "buy" rating re-affirmed by analysts at Wedbush.

AIMMUNE THERAPEUTICS  (AIMT) 
Last aimmune therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.aimmune.com/corporate-profile